Pricing Log in Create free account
Friday 6 November 2026 Export IART’s income statement to Excel — free account

Integra LifeSciences Holdings Corporation

IART Healthcare Medical Devices

Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024.

Revenue
+2.27%
EPS
+371.4%
Free cash flow
+232.9%
Total debt
−0.79%

Quarter to September 2026, against a year earlier

13.98 0.14 −0.99%
Market cap
$1.1B
P/E
83.0×
Fwd P/E
26.0×
Dividend yield
—
F-score
5/9
Altman Z
0.62
Beneish M
−3.25
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 14.02%

Capital & Financial Ratios $m

Size
Market Cap 1,100.00
Revenue ttm 1,656.79
Net income ttm 13.01
Free cash flow ttm 85.78
Net debt Q 1,466.22
Valuation
P/E 83.00 (above 35: high)
Forward P/E 26.00
Price / sales 0.66
Forward P/S Powerpack
Price / FCF 12.73
Price / book 1.02
Financial health
Current ratio Q 3.62 (at or above 1.5: strong)
Debt / equity Q 1.67
Interest coverage Q 0.82
Growth
Revenue growth Q +2.27% (above 0%: growing)
Operating income growth Q +60.70% (above 0%: growing)
EPS, this year +4.71%
EPS, next year A +1.49%
Revenue, next year A +0.54%
EPS, past 5 yrs —
EPS, next 5 yrs A +3.46%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.6×, against a ten-year median of 3.7×; over the ten years it ranged from 1.4× in 2026 to 5.4× in 2021.
P/E against its own 10 years 85.53%
10-year low 10-year high
P/S against its own 10 years 8.62%
10-year low 10-year high
P/B against its own 10 years 10.78%
10-year low 10-year high
EV/Sales against its own 10 years 6.49%
10-year low 10-year high
EV/FCF against its own 10 years 25.04%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 309 274 264 312
Receivables 259 272 279 249
Inventory 390 429 493 464
Other 33 30 28 47
1,058 1,082 1,160 1,190
2023 2024 2025 Q'26
Payables 92 83 96 66
ST’ Debt — 573 88 —
Other 9 10 11 12
307 922 456 329

Compound Annual Growth %

10y 5y 3y
Sales 6.36% 3.57% 1.63%
Cash Flow (7.07%) (24.39%) (42.46%)
Earnings 0.00% 0.00% 0.00%
Book Value 3.34% (7.18%) (16.69%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.56 Actual 0.59

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.79 0.83 Beat by 0.04
Q1 FY26 0.41 0.54 Beat by 0.13
Q2 FY26 0.48 0.56 Beat by 0.08
Q3 FY26 0.56 0.59 Beat by 0.03
Q4 FY26 0.69 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.06) 0.06 0.19 — —
’25 (0.33) (6.31) (0.07) (0.02) (6.74)
’24 (0.04) (0.16) (0.14) 0.25 (0.09)
’23 0.29 0.05 0.24 0.25 0.84
’22 0.39 0.54 0.60 0.63 2.16
’21 0.53 0.41 0.51 0.53 1.98
’20 0.11 0.00 0.38 1.09 1.57
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 392 419 411 — —
’25 383 416 402 435 1,635
’24 369 418 381 443 1,611
’23 381 381 382 397 1,542
’22 377 398 385 398 1,558
’21 360 390 387 406 1,542
’20 354 259 370 389 1,372
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 10 23 96 — —
’25 (11) 9 41 12 50
’24 16 40 22 51 129
’23 26 28 27 59 140
’22 44 66 68 85 264
’21 69 91 83 69 312
’20 21 33 70 80 204
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) 10 86 — —
’25 (40) (11) 26 (5) (45)
’24 0 11 (7) 21 15
’23 12 13 14 34 73
’22 35 57 59 82 233
’21 62 85 75 42 264
’20 4 29 63 72 169
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.8
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 992 1,188 1,472 1,518 1,372 1,542 1,558 1,542 1,611 1,635 1,657 +5.7% 1,644 1,675 1,737 +2.0%
Gross margin, % 64.81 63.35 61.19 62.79 62.03 61.24 62.29 57.39 54.77 50.86 52.36 (13.9) pt
EBT 90 11 57 60 94 215 214 81 (18) (564) 22 n/m
EBT margin, % 9.11 0.96 3.90 3.96 6.82 13.92 13.73 5.26 (1.13) (34.46) 1.35 (43.6) pt
Net income 75 65 61 50 134 169 181 68 (7) (516) 13 n/m
Per share, $
Per share, $ Revenue 13.34 15.45 17.77 17.72 16.21 18.21 18.77 19.25 20.91 21.33 21.41 +5.4%
Earnings 0.94 0.82 0.72 0.58 1.57 1.98 2.16 0.84 (0.09) (6.74) 0.17 n/m
Cash flow 1.56 1.49 2.41 2.70 2.41 3.69 3.19 1.75 1.68 0.66 1.81 (9.2%)
Capex (0.63) (0.56) (0.93) (0.81) (0.42) (0.57) (0.38) (0.83) (1.49) (1.25) (0.71) +7.8%
Free cash flow 0.93 0.93 1.48 1.89 1.99 3.12 2.81 0.91 0.19 (0.59) 1.11 n/m
Book value 11.29 12.51 16.60 16.54 17.90 19.89 21.74 19.83 20.07 13.61 13.78 +2.1%
Shares, m 74 77 83 86 85 85 83 80 77 77 77 +0.3%
Valuation, ×
Valuation, × P/E 46.55 57.16 62.64 100.48 41.20 33.83 25.79 52.11 0.00 0.00 83.00 42.0
P/S 3.19 3.03 2.54 3.29 4.01 3.68 2.97 2.25 1.08 0.58 0.66 2.7
P/B 3.77 3.75 2.72 3.52 3.63 3.37 2.56 2.18 1.13 0.91 1.02 2.8
EV/Sales 3.76 4.40 3.35 4.05 4.77 4.36 3.61 3.06 2.01 1.53 1.60 3.5
EV/FCF 53.81 73.22 40.32 37.99 38.83 25.42 24.11 64.52 129.88 (80.70) 30.84 40.7
Cash, $m
Cash, $m Operating cash flow 116 115 200 231 204 312 264 140 129 50 140 (8.9%)
Capex (47) (43) (77) (69) (35) (48) (31) (67) (114) (96) (55) +8.2%
Free cash flow 69 71 122 162 169 264 233 73 15 (45) 86 n/m
Balance, $m
Balance, $m Working capital 372 473 513 527 836 814 841 751 160 704 861 +7.4%
Net debt 563 1,666 1,216 1,161 1,051 1,048 1,002 1,176 1,496 1,554 1,466 +11.9%
Shareholders’ equity 840 962 1,376 1,417 1,515 1,685 1,804 1,588 1,545 1,043 1,067 +2.4%
Returns, %
Returns, % ROA 4.16 2.58 1.92 1.57 3.87 4.57 4.71 1.77 (0.18) (13.52) 0.36 (17.7) pt
ROIC 5.14 1.07 2.68 2.27 3.69 4.51 5.32 2.52 0.58 (11.87) 1.79 (17.0) pt
ROE 9.37 7.19 5.20 3.60 9.13 10.57 10.35 3.99 (0.44) (39.90) 1.24 (49.3) pt
People
People Employees 3,700 4,400 4,500 4,000 3,700 3,800 3,722 3,946 4,396 4,427 — +2.0%
Revenue/emp, $m 0.27 0.27 0.33 0.38 0.37 0.41 0.42 0.39 0.37 0.37 — +3.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Integra LifeSciences Holdings Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
LMRI Lumexa Imaging Holdings, Inc. $1.3B — (loss-making) 38.0× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
AORT Artivion, Inc. $1.2B — (loss-making) — (loss-making) +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
ATEC Alphatec Holdings, Inc. $1.2B — (loss-making) — (loss-making) +12.55% (above 0%: growing) n/m −149.22% (below 0%: shrinking) 71.55% 1.47% Compare
PRCT PROCEPT BioRobotics Corporation $1.2B — (loss-making) — (loss-making) +17.96% (above 0%: growing) n/m −1.57% (below 0%: shrinking) 66.28% (27.85%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B 83.0× 26.0× +2.27% (above 0%: growing) n/m +232.94% (above 0%: growing) 51.04% 4.60%
IRMD iRadimed Corporation $1.1B 44.9× 39.6× +14.15% (above 0%: growing) +15.91% (above 0%: growing) +18.58% (above 0%: growing) 76.26% 33.63% Compare
SIBN SiBone $1.1B — (loss-making) — (loss-making) +14.49% (above 0%: growing) n/m +31.13% (above 0%: growing) 79.29% (7.81%) Compare
CBLL CeriBell, Inc. $1.0B — (loss-making) — (loss-making) +29.89% (above 0%: growing) n/m −19.65% (below 0%: shrinking) 89.77% (70.03%) Compare
AHCO AdaptHealth Corp. $1.0B — (loss-making) — (loss-making) +10.90% (above 0%: growing) n/m −23.58% (below 0%: shrinking) 15.40% (20.91%) Compare
Median of peers $1.1B — — +13.35% — −10.61% 68.91% (7.23%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 6 April 2026

Ownership

Directors and executive officers, together 3.84%
BlackRock, Inc. 13.19%
Tru St Partnership LP and Provco Leasing Corporation 10.93%
Rubric Capital Management LP 9.44%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Integra LifeSciences Holdings Corporation (IART) Latest News

4 Nov

Impact 3 · · Simply Wall St.

24 Oct

Impact 4 · · Simply Wall St.

22 Oct

Impact 4 · · StockStory
Impact 4 · · Simply Wall St.

21 Oct

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby transcript
Impact 4 · · MarketBeat
Impact 3 · · StockStory
Impact 3 · · The Motley Fool
Impact 3 · · Zacks
Impact 3 · · StockStory
Impact 3 · · Zacks
Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

20 Oct

Impact 3 · · StockStory

19 Oct

Impact 4 · · GlobeNewswire

16 Oct

Impact 3 · · GlobeNewswire

9 Oct

Impact 4 · · GlobeNewswire

8 Oct

Impact 4 · · Simply Wall St.

2 Oct

Impact 4 · · StockStory
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

1 Oct

Impact 3 · · Zacks

30 Sep

Impact 4 ·

29 Sep

Impact 3 · · Zacks
Impact 3 ·

25 Sep

Impact 3 · · GlobeNewswire

23 Sep

Impact 3 · · Simply Wall St.

10 Sep

Impact 3 ·

20 Aug

Impact 4 ·
stockrow.com/IART · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com